Recombinant Mouse C-C chemokine receptor type 1 (Ccr1)

Production and Purification Methods

The production of Recombinant Mouse Ccr1 involves a systematic biotechnological approach. Initially, the mouse Ccr1 protein-encoding gene (1-355 amino acids) is linked to an N-terminal 10×His tag gene to create the target construct. This target gene is then amplified using PCR and cloned into expression vectors, creating recombinant plasmids . Following successful cloning, these plasmids are transfected into an in vitro Escherichia coli expression system, where target proteins are induced during culture .

The expressed proteins are subsequently harvested from the culture supernatant and purified using affinity chromatography, taking advantage of the His-tag's metal-binding properties. This purification process consistently yields recombinant mouse Ccr1 protein with purity exceeding 85%, as validated by SDS-PAGE analysis . The resulting purified protein maintains biological activity and is suitable for various experimental applications, including structural studies, functional assays, and immunological investigations.

Molecular Characterization of Recombinant Mouse Ccr1

Table 1: Characteristics of Recombinant Mouse Ccr1 Protein

These specifications ensure that the recombinant protein closely resembles the native Ccr1 in structure while incorporating features that facilitate its experimental manipulation and analysis. The high purity level (>85%) is particularly important for ensuring that experimental results reflect the genuine properties of Ccr1 rather than contaminants .

Ligand Interactions and Binding Properties

Ccr1 interacts with multiple chemokine ligands, each triggering specific cellular responses. These interactions are central to the receptor's biological functions, particularly in immune cell recruitment and migration. The following table highlights the key ligands of Mouse Ccr1 and their associated functions:

Table 2: Key Ligands of Mouse Ccr1 and Their Functions

When activated by these ligands, Ccr1 triggers a signaling cascade within immune cells, leading to their migration towards the source of the chemokine . For example, binding of CCL3 to Ccr1 mediates neutrophil migration and leads to the sequential release of TNF-alpha and leukotriene B4, important inflammatory mediators . Similarly, activation by CCL5 results in neuroinflammation through the ERK1/2 signaling pathway .

Role in Immune Cell Migration and Recruitment

Ccr1 plays a crucial role in regulating immune cell migration, inflammation, and immune responses . It contributes significantly to the inflammatory response by recruiting various immune cells, including monocytes, macrophages, T-cells, and dendritic cells, to sites of inflammation for the clearance of pathogens and the resolution of tissue damage .

Studies using Ccr1-deficient mice have demonstrated that this receptor is particularly important for neutrophil chemotaxis. In these knockout models, neutrophils failed to chemotax in vitro and failed to mobilize into peripheral blood in vivo when stimulated with MIP-1α . This defect in neutrophil trafficking has significant implications for host defense against certain pathogens, particularly those controlled by neutrophil-mediated immunity.

The receptor is constitutively expressed in multiple immune cell types, including neutrophils, monocytes, eosinophils, and both T and B lymphocytes . This widespread expression across different leukocyte populations underscores Ccr1's fundamental importance in coordinating immune responses and highlights its potential as a therapeutic target in various inflammatory and immune-mediated conditions.

Involvement in Neuroinflammation

Recent research has highlighted the significant role of Ccr1 in neuroinflammation processes. The receptor is expressed in various cell types within the central nervous system (CNS), including microglia and astrocytes, and has been implicated in the disruption of the blood-brain barrier (BBB) during neuroinflammatory diseases .

Activation of Ccr1 in the central nervous system can lead to increased neuroinflammation, which is associated with conditions such as cerebral hemorrhage and multiple sclerosis . Studies have demonstrated that Ccr1 activation promotes neuroinflammation specifically through the ERK1/2 signaling pathway . This mechanistic understanding provides potential targets for therapeutic intervention in neurological disorders with an inflammatory component.

The involvement of Ccr1 in neuroinflammation represents an important area for future research, particularly regarding the development of targeted therapies for neurological disorders. Modulating Ccr1 activity could potentially help manage the inflammatory component of various CNS diseases, improving outcomes for patients affected by these conditions.

Development and General Characteristics

Studies using Ccr1-deficient mice have provided valuable insights into the non-redundant functions of this receptor in vivo. These knockout mice were generated through targeted gene disruption, replacing a 352-bp fragment of the Ccr1 open reading frame with a neomycin resistance cassette . The resulting mice lack functional Ccr1 but appear phenotypically normal when raised in specific pathogen-free environments.

Ccr1-deficient mice are viable and fertile, exhibiting normal growth, development, anatomy, and behavior compared to wild-type littermates . They have been observed for up to 20 months of age without displaying defects in hemostasis or wound healing, or increased susceptibility to spontaneous infection under standard laboratory conditions .

Histological examination of bone marrow, lymph node, spleen, and thymus revealed no significant differences between Ccr1-deficient mice and wild-type littermates . Similarly, complete blood count and differential analyses showed normal distribution of mature leukocytes. This suggests that while Ccr1 plays important roles in immune function, its absence does not significantly affect basic physiological processes under normal conditions.

Immune Function and Response to Challenges

Despite appearing normal under standard conditions, Ccr1-deficient mice exhibit significant functional deficits when challenged. The following table summarizes the key phenotypic characteristics observed in these knockout models:

Table 3: Phenotypic Characteristics of Ccr1-Deficient Mice

One of the most notable phenotypic features is the impaired neutrophil function. Neutrophils from Ccr1-deficient mice fail to chemotax in vitro and fail to mobilize into peripheral blood in vivo in response to MIP-1α . Consistent with this defect, Ccr1-deficient mice exhibited accelerated mortality when challenged with Aspergillus fumigatus, a fungus controlled primarily by neutrophil-mediated immunity .

These findings highlight the non-redundant role of Ccr1 in neutrophil function and host defense against certain pathogens, particularly those requiring effective neutrophil recruitment and activation for their clearance.

Infection and Host Defense

The importance of Ccr1 in host defense is particularly evident in models of fungal infection. Ccr1-deficient mice showed accelerated mortality when challenged with Aspergillus fumigatus, demonstrating the receptor's crucial role in antifungal defense . This susceptibility is likely due to the impaired neutrophil chemotaxis and mobilization observed in these animals, as neutrophils are primary effectors in controlling fungal infections.

The phenotype of Ccr1-deficient mice is analogous to that previously described for MIP-1α-deficient mice, which also appear phenotypically normal under standard conditions but exhibit impaired inflammatory responses to microbial challenges, including Coxsackie B and influenza viruses . This parallel suggests a critical interaction between MIP-1α and Ccr1 in orchestrating effective antimicrobial immune responses.

These findings have significant implications for understanding host defense mechanisms and potential immunodeficiencies associated with Ccr1 dysfunction. They also highlight the potential risks of therapeutic interventions targeting Ccr1, as inhibition of this receptor might compromise host defense against certain pathogens.

Inflammatory Responses and Granuloma Formation

Ccr1 plays a significant role in inflammatory processes, particularly in granulomatous inflammation. In a model using Schistosoma mansoni eggs, Ccr1-deficient mice exhibited a 40% reduction in the size of lung granulomas compared to wild-type littermates . This reduction in granuloma size demonstrates the important contribution of Ccr1 to the development and maintenance of inflammatory lesions.

Ccr1 deficiency was also associated with altered cytokine production. In the granuloma model, lung lymph node cells from Ccr1-deficient mice produced increased levels of interferon-γ and decreased levels of interleukin-4 when stimulated with egg-specific antigen . This shift suggests that Ccr1 influences the inflammatory response not only through direct effects on leukocyte chemotaxis but also by modulating the balance between type 1 and type 2 cytokine responses.

Hematopoiesis and Progenitor Cell Trafficking

Ccr1 and its ligands, particularly MIP-1α, have been implicated in the regulation of myeloid stem and progenitor cell proliferation and mobilization . Studies with Ccr1-deficient mice have revealed specific defects in the trafficking and proliferation of myeloid progenitor cells both under steady-state conditions and following stimulation.

While there were no differences in the absolute numbers of progenitors per femur between Ccr1-deficient and wild-type mice, significantly decreased numbers of granulocyte-macrophage colony-forming units (CFU-GM) and granulocyte, erythrocyte, macrophage, megakaryocyte colony-forming units (CFU-GEMM) were observed in the spleen and circulating blood of Ccr1-deficient mice . This finding suggests that Ccr1 is involved in the mobilization of progenitor cells from the bone marrow to peripheral sites and their subsequent proliferation, particularly in the spleen.

These observations indicate an important role for Ccr1 in hematopoiesis, specifically in the trafficking and distribution of myeloid progenitor cells. This function could have implications for understanding disorders of hematopoiesis and for developing strategies to enhance hematopoietic recovery following chemotherapy or radiation therapy.

Potential Applications in Inflammatory Disorders

The involvement of Ccr1 in various inflammatory processes suggests potential therapeutic applications for Ccr1 modulators. The reduced granuloma formation observed in Ccr1-deficient mice indicates that Ccr1 antagonists might be effective in treating granulomatous diseases . Similarly, given the role of Ccr1 in neuroinflammation, modulating its activity could potentially benefit patients with neurological disorders that have an inflammatory component, such as multiple sclerosis .

Interestingly, humans homozygous for inactivating mutations in other chemokine receptor genes, such as CCR5 and Duffy, have been identified and do not exhibit obvious health problems . In fact, these individuals appear to be resistant to certain infectious diseases, specifically HIV-1 in the case of CCR5 deficiency and malaria in the case of Duffy deficiency . This suggests that targeting chemokine receptors, including potentially Ccr1, might offer therapeutic benefits with acceptable safety profiles in humans.

Research Challenges and Future Directions

Several challenges and opportunities exist for future research on Recombinant Mouse Ccr1. High-resolution structural studies using techniques such as cryo-electron microscopy could provide valuable insights for the rational design of selective Ccr1 modulators. Additionally, the development of cell-specific or tissue-specific Ccr1 knockout models would help dissect the contribution of Ccr1 expressed by different cell types to various physiological and pathological processes.

Translational studies are needed to determine whether findings from mouse models can be extrapolated to human physiology and pathology. Comparative studies of mouse and human Ccr1, including their expression patterns, ligand specificities, and signaling properties, would be valuable for assessing the potential of Ccr1-targeted therapies in human diseases.

The development and preclinical evaluation of selective Ccr1 modulators, including both antagonists and potentially agonists for specific applications, represents an important step toward translating the basic scientific understanding of Ccr1 biology into clinical applications that could benefit patients with inflammatory, immune-mediated, and perhaps even certain infectious diseases.